mug147 Antibody

What is CD147 and why is it significant in research applications?

CD147 (Cluster of Differentiation 147) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays crucial roles in cellular processes including tumor progression, cell-cell interactions, and matrix metalloproteinase induction. The significance of CD147 in research stems from its involvement in multiple biological processes:

• Serves as a receptor for cyclophilins and participates in inflammatory responses

• Functions as a chaperone for monocarboxylate transporters

• Associated with tumor cell invasion and metastasis through stimulation of matrix metalloproteinase production

• Identified as the OK blood group antigen in erythrocytes

• Also known as Basigin, EMMPRIN, and Tumor cell-derived collagenase stimulatory factor

Research applications frequently target CD147 to understand its role in cancer progression, inflammatory diseases, and cellular metabolism.

How do I select between polyclonal and monoclonal CD147 antibodies for my experiments?

Selection between polyclonal and monoclonal CD147 antibodies should be based on your specific experimental requirements:

Polyclonal antibodies:

• Recognize multiple epitopes of CD147, providing stronger signals in applications like Western blotting and immunohistochemistry

• Offer greater detection sensitivity, especially for proteins expressed at low levels

• More tolerant to minor protein denaturation or modifications

• Less affected by minor antigen changes across species

Monoclonal antibodies:

• Provide higher specificity by recognizing a single epitope

• Ensure consistent lot-to-lot reproducibility

• Often preferred for quantitative studies requiring high precision

• Better for distinguishing between closely related protein isoforms

For initial characterization of CD147 in a new model system, polyclonal antibodies might be preferable, while monoclonal antibodies are better for standardized detection protocols or when differentiating between specific conformational states of CD147 .

What validation steps should I perform before using a new CD147 antibody?

Thorough validation is essential before incorporating a new CD147 antibody into your research:

• Western blot analysis: Verify the antibody detects a protein of the expected molecular weight for CD147 (~35-65 kDa depending on glycosylation)

• Positive and negative controls: Test the antibody on cell lines known to express high levels of CD147 (e.g., A431 cells) and compare with low-expressing or knockout cell lines

• Epitope competition assay: Pre-incubate the antibody with purified CD147 protein to confirm binding specificity

• Cross-reactivity assessment: Test the antibody against related proteins to ensure specificity

• Immunoprecipitation followed by mass spectrometry: Confirm the identity of the precipitated protein

• Functional validation: Evaluate if the antibody blocks known CD147 functions in vitro

• Comparison with established CD147 antibodies: Compare staining patterns with previously validated antibodies

How can I optimize immunohistochemistry protocols with CD147 antibodies?

Optimizing immunohistochemistry (IHC) with CD147 antibodies requires attention to several key factors:

• Fixation method: CD147 epitopes can be sensitive to overfixation. For formalin-fixed paraffin-embedded tissues, limit fixation to 24 hours and consider antigen retrieval methods.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) typically works well for CD147 detection.

• Blocking protocol: Use 5-10% normal serum from the same species as the secondary antibody plus 1% BSA to reduce background.

• Antibody dilution: Optimize through titration, typically starting at manufacturer's recommendation (e.g., 1:100 to 1:500 for most commercial CD147 antibodies).

• Incubation conditions: For stronger signal, consider overnight incubation at 4°C rather than 1-2 hours at room temperature.

• Detection system: For low expression levels, amplification systems like tyramide signal amplification may improve sensitivity.

• Counterstaining: Hematoxylin works well but should be optimized to not obscure membrane staining patterns typical of CD147.

Always include positive controls such as tumor tissues known to express high levels of CD147 and negative controls by omitting primary antibody or using non-specific IgG .

What are effective strategies for using CD147 antibodies in combination with other markers?

Multiparameter analysis with CD147 requires careful consideration of antibody compatibility:

• Panel design considerations:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • When using fluorescence-based detection, choose fluorophores with minimal spectral overlap

  • Consider the subcellular localization of each target (membrane for CD147)

• Optimization approach:

  • First optimize conditions for each antibody individually

  • For multiplexed immunofluorescence, test antibodies sequentially, starting with the most sensitive/difficult marker

  • For flow cytometry, perform compensation controls with single-stained samples

  • Use appropriate blocking between sequential staining steps to minimize cross-reactivity

• Validated combinations:

  • CD147 with matrix metalloproteinases (MMPs) for invasion studies

  • CD147 with MCT1/MCT4 for metabolic research

  • CD147 with phosphorylated EGFR and Akt for tumor signaling research

How do I troubleshoot weak or inconsistent CD147 antibody staining?

When encountering weak or inconsistent CD147 staining, consider these troubleshooting approaches:

Always validate any protocol modifications with appropriate controls before applying to experimental samples .

How should I quantify CD147 expression in immunohistochemistry studies?

Quantification of CD147 expression in IHC requires standardized approaches:

• Semi-quantitative scoring methods:

  • Intensity score: 0 (negative), 1+ (weak), 2+ (moderate), 3+ (strong)

  • Percentage score: Estimate percentage of positive cells (0-100%)

  • H-score: Multiply intensity by percentage (range 0-300)

  • Quick score: Sum of intensity (0-3) and percentage (0-6 for 0%, 1-10%, 11-30%, 31-50%, 51-70%, 71-90%, >90%)

• Digital image analysis:

  • Use software platforms (ImageJ, QuPath, Aperio) for automated quantification

  • Establish staining thresholds using positive and negative controls

  • Consider membrane-specific algorithms for CD147 (typically membrane-localized)

  • Report metrics like optical density, H-score, or percentage positive area

• Standardization requirements:

  • Use tissue microarrays when possible to ensure uniform staining conditions

  • Include reference standards on each slide

  • Blind scorers to experimental conditions

  • For clinical studies, have multiple independent pathologists score

  • Report inter-observer variability statistics

For research requiring precise quantification, digital image analysis provides more objective and reproducible results than manual scoring .

How do I interpret apparent contradictions in CD147 antibody experimental results?

When faced with contradictory results using CD147 antibodies, consider these potential sources and resolution strategies:

• Epitope accessibility differences:

  • Different antibodies recognize distinct epitopes that may be differentially accessible

  • Solution: Use multiple antibodies targeting different CD147 epitopes

• Glycosylation effects:

  • CD147 exists in heavily glycosylated (~45-65 kDa) and less glycosylated (~32 kDa) forms

  • Some antibodies may preferentially recognize specific glycoforms

  • Solution: Use enzymatic deglycosylation to confirm protein identity

• Experimental condition variations:

  • Cell signaling changes can alter CD147 conformation and antibody accessibility

  • For example, exposure to AG1478 (EGFR inhibitor) increased mAb 806 binding to cells overexpressing wild-type EGFR but decreased binding to cells expressing mutant de2-7 EGFR

  • Solution: Standardize experimental conditions and cell treatment protocols

• Confirmation strategies:

  • Use orthogonal detection methods (flow cytometry, Western blot, immunofluorescence)

  • Employ genetic approaches (siRNA knockdown, CRISPR knockout) to validate specificity

  • Perform functional assays to correlate expression with biological activity

When reporting contradictory results, clearly document antibody clones, experimental conditions, and cell types to facilitate interpretation by the scientific community .

How can CD147 antibodies be used to investigate tumor-microenvironment interactions?

CD147 antibodies provide valuable tools for studying tumor-microenvironment interactions:

• Matrix remodeling studies:

  • Use CD147 antibodies in combination with MMP antibodies to investigate how CD147 stimulates matrix degradation

  • Co-culture experiments with tumor cells and stromal cells can reveal paracrine MMP induction mechanisms

  • Blocking antibodies can help determine if CD147-mediated interactions are responsible for observed effects

• Angiogenesis research:

  • CD147 promotes tumor angiogenesis through VEGF-dependent and independent mechanisms

  • Antibodies can help visualize CD147 expression in tumor vasculature and assess correlation with vascular density

  • Functional blocking antibodies can determine the contribution of CD147 to angiogenic processes

• Inflammatory cell interactions:

  • CD147 mediates interactions between tumor cells and inflammatory cells

  • Multicolor flow cytometry with CD147 and immune cell markers can identify specific interaction partners

  • Spatial analysis in tissue sections can reveal colocalization patterns

• Metabolic coupling studies:

  • CD147 regulates lactate transporters (MCT1/MCT4) that are important for metabolic symbiosis in tumors

  • Antibodies against CD147 and MCTs can reveal metabolic compartmentalization in the tumor microenvironment

What considerations are important when designing therapeutic CD147 antibody studies?

When designing studies to evaluate therapeutic potential of CD147 antibodies, consider:

• Antibody characteristics:

  • Isotype selection affects immune effector functions (IgG1 vs. IgG4)

  • Fc region engineering can enhance or diminish ADCC/CDC activity

  • Humanization status affects immunogenicity in animal models

• Mode of action assessment:

  • Direct antiproliferative effects: Use cell viability assays (e.g., MTS assay as described for mAb 806)

  • Immune-mediated effects: Include ADCC and CDC assays

  • Combination effects: Test with standard chemotherapies or targeted agents

  • Signaling inhibition: Assess effects on downstream pathways (e.g., phosphorylated Akt)

• In vivo model considerations:

  • Select models with appropriate CD147 expression levels

  • Consider both preventative (before tumor establishment) and therapeutic (established tumor) models

  • Include detailed pharmacokinetic/pharmacodynamic analysis

  • Use both immunocompromised and immunocompetent models if possible

• Combination therapy design:

  • The combination of antibodies with small molecule inhibitors may show synergistic effects, as demonstrated with mAb 806 and AG1478 (EGFR inhibitor), where the combination produced greater antitumor activity than either agent alone in xenograft models

  • Include appropriate single-agent controls

  • Determine optimal dosing sequence and schedule

  • Assess potential mechanisms of resistance

• Biomarker development:

  • Identify predictive biomarkers for response

  • Develop pharmacodynamic markers to confirm target engagement

  • Consider heterogeneity of CD147 expression within tumors

What are the latest methodological advances in CD147 antibody engineering for research applications?

Recent methodological advances in CD147 antibody engineering include:

• Bispecific antibody platforms:

  • Creation of antibodies targeting both CD147 and another tumor marker

  • Development of CD147 x CD3 bispecifics to redirect T cells to tumor cells

  • These constructs enable novel functional studies not possible with conventional antibodies

• Intrabody approaches:

  • Engineering antibodies with subcellular targeting signals

  • Allows interference with CD147 function in specific cellular compartments

  • Useful for dissecting the role of CD147 in different intracellular locations

• Site-specific conjugation methods:

  • Development of antibody-drug conjugates with precise drug-antibody ratios

  • Creation of antibody-fluorophore conjugates with defined labeling sites

  • These approaches minimize the impact of conjugation on antigen binding

• Nanobody and single-chain antibody derivatives:

  • Smaller antibody formats enable better tissue penetration

  • Useful for super-resolution microscopy applications

  • Allow for novel engineering approaches due to their modular nature

• Conditional activation strategies:

  • Photactivatable antibodies that can be triggered by light

  • Protease-activated antibodies that become active in the tumor microenvironment

  • These tools enable spatiotemporal control of CD147 targeting

How should I validate knockdown or knockout models when studying CD147 functions?

Proper validation of CD147 genetic manipulation models requires:

• Expression validation at multiple levels:

  • mRNA level: RT-qPCR with primers targeting different regions of CD147 transcript

  • Protein level: Western blotting using antibodies recognizing different epitopes

  • Cell surface expression: Flow cytometry with non-competing antibody clones

  • All approaches should be quantitative and include appropriate controls

• Functional validation:

  • MMP induction assays: Measure secreted MMPs in conditioned media

  • Invasion assays: Assess changes in invasive capacity

  • Metabolic assays: Evaluate lactate transport with MCT1/4 function tests

  • Each assay should include positive controls (e.g., pharmacological inhibitors of the pathway)

• Rescue experiments:

  • Re-expression of wild-type CD147 should restore function in knockout models

  • Use of expression vectors resistant to siRNA for knockdown models

  • Include structure-function studies with mutant CD147 variants

• Off-target effect assessment:

  • For CRISPR approaches, include multiple guide RNAs targeting different regions

  • For RNAi approaches, use multiple non-overlapping siRNAs/shRNAs

  • Include analysis of closely related family members to ensure specificity

• Temporal considerations:

  • Acute vs. chronic loss may produce different phenotypes due to compensation

  • Inducible systems can distinguish between developmental and acute effects

  • Time-course experiments can reveal primary vs. secondary consequences of CD147 loss

How can I integrate CD147 antibody-based studies with other emerging technologies?

Integration of CD147 antibody-based research with cutting-edge technologies offers new insights:

• Spatial transcriptomics integration:

  • Combine CD147 antibody staining with spatial transcriptomics to correlate protein expression with local gene expression profiles

  • This reveals potential regulatory mechanisms and microenvironmental influences on CD147 function

  • Analytical approaches include registration of sequential sections or multiplex platforms that allow protein and RNA detection on the same section

• Single-cell approaches:

  • Link CD147 protein levels (by index sorting) with single-cell RNA-seq

  • Reveals cellular states associated with different CD147 expression levels

  • Can identify novel CD147-associated pathways not evident in bulk analysis

• Proximity labeling methodologies:

  • Use antibody-directed enzyme-mediated proximity labeling to identify CD147 interaction partners

  • Approaches include antibody-conjugated APEX2 or TurboID enzymes

  • Provides spatial context to protein-protein interactions in intact cells

• Live-cell imaging applications:

  • Non-blocking CD147 antibody fragments conjugated to bright, photostable fluorophores

  • Enable tracking of CD147 dynamics in living cells

  • Can be combined with optogenetic approaches to manipulate CD147 function

• Computational biology integration:

  • Machine learning approaches to analyze complex staining patterns

  • Systems biology models incorporating CD147 signaling networks

  • These computational approaches can generate novel hypotheses for experimental testing